Ieramilimab

DB16419InvestigationalProtein Based Therapies

Ieramilimab is under investigation in clinical trial NCT02460224 (Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.).

Mechanism: Pharmacologically active on Lymphocyte activation gene 3 protein
Curator reviewed
Code names: Humanised IMP-701 · LAG-525

Resolves to

Compound

UNIIOI8P0SFD4RCAS2137049-37-5

Targets

P18627LAG3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ieramilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account